Research synthesisModerate evidenceLarge effect3 studies · 3 beneficial · 0 neutral · 0 harmful
Across all 3 studies, Bacillus coagulans MTCC 5856 consistently shows beneficial effects on reducing abdominal pain, with predominantly large effect sizes. The evidence includes a large systematic review (n=9253) and two smaller randomized controlled trials in adults with IBS or functional gas and bloating. The most studied dose is approximately 2 × 10^9 CFU/day (2 billion spores/day), and effects are observed in clinical populations with IBS or functional bloating.
- Effective dose range: 2 × 10^9 CFU/day (2 billion spores/day)
- Studied populations: adults with IBS, adults with diarrhea-predominant IBS, adults with functional gas and bloating
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Study durations were not consistently reported, and one trial (n=36) had a very small sample size.
Generated Jun 12, 2026